BRIDGE - Blocking Receptor of IL-1β for Donor Graft Edema Reduction

Conditions

• Lung Transplant Recipient

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Anakinra — DRUG
  100 mg injection

Study Details

This study will determine if primary graft dysfunction (which causes low blood oxygen levels and fluid or inflammation in the lungs) after lung transplant can be prevented through the use of the study drug (IL-1 receptor antagonist, Anakinra). In this study, lung transplant participants who are randomized to the treatment group will have the study drug injected into the solution that their donor lungs are kept in prior to transplant.

Key Dates

Start date

Feb 1, 2026

Status verified

Feb 2026

Primary completion

Aug 31, 2027

Completion

Dec 31, 2027

Study Design

Enrollment

20 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Treatment group: Anakinra during EVLP
  One dose (100mg) Anakinra will be injected into the perfusion solution during ex vivo lung perfusion (EVLP) prior to lung transplant.
• No Intervention: Control group
  Control group will not receive Anakinra during EVLP.

Primary Outcome Measure

Primary graft dysfunction after lung transplant [ Time Frame: 3 days post lung transplant ]

Central Contacts

• Mary Carns, MS
  312-503-1137
  [email protected]

Locations (1)

Find similar trials in Chicago, IL